摘要
结直肠癌(Colorectal cancer,CRC)患者中约25%确诊时已发生远处转移,疾病复发率也高达50%~60%,因此,针对中晚期CRC患者,已错过手术最佳时机,而传统的放化疗效果并不理想。分子靶向治疗可针对明确的致癌基因片段或蛋白分子,使用对应药物,在不影响周围正常细胞的同时,可与致癌点位特异性结合,以使癌细胞凋亡。目前分子靶向治疗药物,主要包括抑制肿瘤血管生成为靶点的治疗及表皮生长因子受体(Epidermal growth factor receptor,EGFR),为中晚期CRC患者带来新的希望。
About 25% of colorectal cancer(CRC) patients have been presenting with distant metastasis at diagnosis,and the disease recurrence rate of the disease reaches 50%to 60%. Therefore, the optimal timing of operation has been missed for advanced CRC patients,and the effect of traditional chemoradiotherapy is not satisfactory.Molecular targeted therapy, which targetsat specific oncogene fragments or protein molecules,uses corresponding drugs to induce the carcinoma cell apoptosis via specific binding with carcinogenic sites without affecting the surrounding normal cells.Current molecular targeted therapeutic drugs mainly include tumor angiogenesis inhibitors and epidermal growth factor receptor(EGFR),which bring new hope for advanced CRC patients.
作者
王庆
WANG Qing(Tianjin People's Hospital,Tianjin 300121,China)
出处
《现代诊断与治疗》
CAS
2021年第11期1709-1711,共3页
Modern Diagnosis and Treatment
关键词
结直肠癌
中晚期
分子靶向治疗
Colorectal cancer
Advanced stage
Molecular targeted therapy
